R G Miller1, T L Munsat, M Swash, B R Brooks. 1. Chairman Clinical Trials Consortium for the Research Group on Motor Neuron Diseases, World Federation of Neurology, Forbes Norris MDA/ALS Center, Department of Neurology, California Pacific Medical Center, San Francisco 94115, USA. rmiller@cooper.cpmc.org
Abstract
BACKGROUND: In 1994 consensus guidelines were developed for conducting clinical trials in ALS. With growing experience in clinical trials, it has become clear that a number of further guidelines were needed. METHODS: Under the auspices of the World Federation of Neurology Committee on Research, a multinational group of neurologists, statisticians, patient advocates, representatives from the pharmaceutical industry as well as regulatory agencies developed consensus about a number of revisions to the existing guidelines during a 2 day conference in April 1998. RESULTS: Expanded areas of focus include greater protection of patient rights, more detailed guidelines for outcome measures statistical analyses, disclosure of study results and improved interaction between investigators and the corporate sector. COMMENT: Substantial progress has been made in standardizing and improving the quality of clinical trials in ALS through these consensus guidelines.
BACKGROUND: In 1994 consensus guidelines were developed for conducting clinical trials in ALS. With growing experience in clinical trials, it has become clear that a number of further guidelines were needed. METHODS: Under the auspices of the World Federation of Neurology Committee on Research, a multinational group of neurologists, statisticians, patient advocates, representatives from the pharmaceutical industry as well as regulatory agencies developed consensus about a number of revisions to the existing guidelines during a 2 day conference in April 1998. RESULTS: Expanded areas of focus include greater protection of patient rights, more detailed guidelines for outcome measures statistical analyses, disclosure of study results and improved interaction between investigators and the corporate sector. COMMENT: Substantial progress has been made in standardizing and improving the quality of clinical trials in ALS through these consensus guidelines.
Entities:
Keywords:
Biomedical and Behavioral Research; World Federation of Neurology
Authors: B Scherrer; S Andrieu; P J Ousset; G Berrut; J F Dartigues; B Dubois; F Pasquier; F Piette; P Robert; J Touchon; P Garnier; H Mathiex-Fortunet; B Vellas Journal: J Nutr Health Aging Date: 2015-12 Impact factor: 4.075
Authors: Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu Journal: Neurology Date: 2017-06-14 Impact factor: 9.910
Authors: P Valsasina; F Agosta; B Benedetti; D Caputo; M Perini; F Salvi; A Prelle; M Filippi Journal: J Neurol Neurosurg Psychiatry Date: 2006-10-09 Impact factor: 10.154
Authors: Jeban Ganesalingam; Daniel Stahl; Lokesh Wijesekera; Clare Galtrey; Christopher E Shaw; P Nigel Leigh; Ammar Al-Chalabi Journal: PLoS One Date: 2009-09-22 Impact factor: 3.240